Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data reported Tuesday show.

An experimental Alzheimer’s therapy from Roche successfully cleared a protein that’s a hallmark of the disease from patients’ ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Essence may receive compensation for some links to products and services on this website. Offers may be subject to change ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is ... wins from the Food and Drug Administration ...

A modified dosing regimen with Eli Lilly’s Alzheimer’s drug Kisunla (donanemab) has shown a reduction in amyloid-related ...

A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in a trial, the company said Tuesday. In the phase 3 study ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify ...

The stock of Eli Lilly and Company LLY has declined 10.6% in a month ... Lilly is also making rapid pipeline progress in ...

A U.K. watchdog has declined to endorse Eli Lilly’s (NYSE:LLY) Alzheimer’s drug donanemab for use in the country's national health service (NHS), noting that therapy was too costly to warrant ...